suggested that the current PD-1/CTLA-4 inhibitor combination therapy has a limited effect in advanced NSCLC patients with high and/or low PD-L1, but may be an effective and tolerable option in the PD-L1-negative subgroup (54). This evidence concerns the gene CD274 and non-small cell lung carcinoma.